NHI approves first patient for NT$49 million muscle atrophy drug

Taiwan's National Health Insurance (NHI) system has approved its first-ever patient to receive a one-time NT$49 million (US$1.53 million) drug for spinal muscular atrophy (SMA), which was added to a list of covered treatments earlier this month, an official said Monday.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)